Immunome, Inc.
NASDAQ:IMNMBiotechnology
-$0.42 today
- Market cap
- $2.03B
- Beta
- 2.07
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.99
Volume 1.03M
Average 1.23M
IMNM EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Immunome, Inc.NASDAQ: IMNM
EPS (Diluted) · Q3 FY2026 · quarter ended Sep 2026
EPS (Diluted) remains negative
Q3 FY2026 EPS (Diluted) was -$0.76, compared with -$0.65 a year earlier. Trailing-twelve-month EPS (Diluted) was -$2.65.
Context
- EPS (Diluted) grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 11 analysts of -$2.51 (-3.4%) for the fiscal year ending Dec 2026, a slowdown from the +51.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$0.76-16.9% QoQ
- Last fiscal yearDec 2025
- -$2.43+51.4% YoY
- LTMSep 2026
- -$2.65+10.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -16.9% | +4.7% | +21.6 pp |
| 1 year | +51.4% | -3.4% | -54.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (2.43) USD
- Year-over-year change
- +51.4%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.43) | +51.4% |
| FY2024 | 2024-12-31 | (5.00) | +7.1% |
| FY2023 | 2023-12-31 | (5.38) | -74.1% |
| FY2022 | 2022-12-31 | (3.09) | -44.4% |
| FY2021 | 2021-12-31 | (2.14) | — |
EPS (Diluted) vs competitors
How IMNM compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
- Its year-over-year change of +10.2% is the 4th highest of 11, against a peer median of -12.1%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | -$0.2 USD | +31.5% | — | |
| LTM Mar 2026 | -$0.38 USD | +11.2% | — | |
| LTM Mar 2026 | -$0.55 USD | +43.9% | — | |
| LTM Mar 2026 | -$0.92 USD | -29.6% | — | |
| LTM Mar 2026 | -$1.1 USD | -23.6% | — | |
| LTM Mar 2026 | -€1.71 EUR | -1040.0% | — | |
| LTM Sep 2026 | -$2.65 USD | +10.2% | — | |
| LTM Mar 2026 | -$3.15 USD | -0.6% | — | |
| LTM Mar 2026 | -$3.53 USD | +6.4% | — | |
| LTM Sep 2026 | -$4.31 USD | -27.5% | — | |
| LTM Mar 2026 | -$307.72 USD | -936.1% | — | |
| Peer median (excluding IMNM) | — | -12.1% | — | |
Competitors are the stored peer set for IMNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 14.02M | 9.04M | 6.94M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.96M |
| Gross Profit | 0 | 0 | 14.02M | 9.04M | 3.99M |
| Gross Margin | — | — | 100.0% | 100.0% | 57.4% |
| Research & Development | 14.11M | 23.27M | 23.09M | 129.54M | 174.33M |
| Selling, General & Admin | 11.09M | 13.63M | 19.66M | 32.96M | 43.77M |
| Operating Expenses | 25.2M | 36.9M | 123.55M | 314.84M | 218.1M |
| Depreciation & Amortization | 755K | 631K | 728K | 2.1M | 2.96M |
| EBITDA | (23.95M) | (36.26M) | (28M) | (151.35M) | (209.44M) |
| EBITDA Margin | — | — | -199.7% | -1674.1% | -3017.4% |
| Operating Income | (25.2M) | (36.9M) | (109.53M) | (305.8M) | (214.11M) |
| Operating Margin | — | — | -781.4% | -3382.4% | -3084.8% |
| Interest Income | 10K | 5K | 2.72M | 12.84M | 11.72M |
| Interest Expense | 10K | 5K | 0 | 0 | 0 |
| Other Income / Expenses | 493K | 5K | 2.72M | 12.84M | 1.72M |
| Income Before Tax | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Pre-Tax Margin | — | — | -761.9% | -3240.4% | -3060.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Net Margin | — | — | -761.9% | -3240.4% | -3060.0% |
| EPS (Basic) | (2.14) | (3.09) | (5.38) | (5.00) | (2.43) |
| EPS (Diluted) | (2.14) | (3.09) | (5.38) | (5.00) | (2.43) |
| Weighted Avg Shares | 11.54M | 12.13M | 19.84M | 58.64M | 87.35M |
| Weighted Avg Shares (Diluted) | 11.54M | 12.13M | 19.84M | 58.64M | 87.35M |
Immunome, Inc.
NASDAQ:IMNM
Intrinsic Alpha fair value
Locked
Current Price
$17.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.